Open drug discovery of anti-virals critical for Canada’s pandemic strategy

FACETS

David Patrick¹  Tania Bubela²  E. Richard Gold³  Vivek Goel⁴  Max Morgan⁵  Aled Edwards⁶  Karen Mossman⁷  Jason Nickerson⁸ 

[1] British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada;Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada;Faculty of Law, McGill University, Montreal, QC H3A 1W9, Canada;Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M6, Canada;M4K Pharma, Inc., Toronto, ON M5G 1L7, Canada Structural Genomics Consortium (SGC), Toronto, ON M5G 1L7, Canada;Molecular Genetics and Medical Biophysics, University of Toronto, Toronto, ON M5G 1L5, Canada SGC, London, UK;Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4L8, Canada;University of Ottawa, Ottawa, ON K1N 6K5, Canada Bruyère Research Institute, Ottawa, ON K1N 5C8, Canada;

关键词: open science;    covid-19;    pandemic preparedness;    drug discovery;    market failure;    intellectual property rights;    public private partnerships;   

DOI  :  10.1139/facets-2020-0079

来源: DOAJ

【 摘 要 】

In the event of the current COVID-19 pandemic and in preparation for future pandemics, open science can support mission-oriented research and development, as well as commercialization. Open science shares skills and resources across sectors; avoids duplication and provides the basis for rapid and effective validation due to full transparency. It is a strategy that can adjust quickly to reflect changing incentives and priorities, because it does not rely on any one actor or sector. While eschewing patents, it can ensure high-quality drugs, low pricing, and access through existing regulatory mechanisms. Open science practices and partnerships decrease transaction costs, increase diversity of actors, reduce overall costs, open new, higher-risk/higher-impact approaches to research, and provide entrepreneurs freedom to operate and freedom to innovate. We argue that it is time to re-open science, not only in its now restricted arena of fundamental research, but throughout clinical translation. Our model and attendant recommendations map onto a strategy to accelerate discovery of novel broad-spectrum anti-viral drugs and clinical trials of those drugs, from first-in-human safety-focused trials to late stage trials for efficacy. The goal is to ensure low-cost and rapid access, globally, and to ensure that Canadians do not pay a premium for drugs developed from Canadian science.

【 授权许可】

Unknown